| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1325 | |
| Phytochemical name or plant extracts | Artemisinin | |
| PMID | 32862573 | |
| Literature evidence | DAPI and comet assays revealed that artemisinin induced powerful apoptotic effects, triggering significant dose-dependent DNA damage. | |
| IUPAC name | (1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one | |
| Phytochemicals’ class or type of plant extracts | Sesquiterpene lactone | |
| Source of phytochemicals or plant Extracts | Artemisia annua | |
| Geographical availability | Afghanistan, Algeria, Altay, Amur, Borneo, Bulgaria, Buryatiya, Central European Rus, China North-Central, China South-Central, China Southeast, Chita, Cyprus, East European Russia, East Himalaya, Egypt, Greece, Hainan, India, Inner Mongolia, Iran, Iraq, Irkutsk, Japan, Jawa, Kazakhstan, Khabarovsk, Kirgizstan, Korea, Krasnoyarsk, Krym, Lebanon-Syria, Lesser Sunda Is., Libya, Malaya, Maluku, Manchuria, Mongolia, Morocco, Myanmar, Nepal, North Caucasus, Northwest European R, Pakistan, Philippines, Primorye, Qinghai, Romania, South European Russi, Sulawesi, Sumatera, Tadzhikistan, Taiwan, Tibet, Transcaucasus, Tunisia, Turkey, Turkey-in-Europe, Turkmenistan, Tuva, Uzbekistan, Vietnam, West Himalaya, Western Sahara, Xinjiang | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Prostate cancer, Lung cancer, Colorectal cancer, Cervical cancer | |
| Target gene or protein | CDK4, Cyclin-B1, Cyclin D1, Cyclin E, ER , miR-34a ,TSP50 | |
| Gene or Protein evidence | Artemsinin and artesunate increased miR-34a expression in a dose-dependent manner correlating with down-regulation of the miR-34a target gene, CDK4. Artemisinin strongly downregulated ERalpha protein and transcripts without altering expression or activity of ERbeta. 25-methoxyl-dammarane-3?, 12?, 20-triol and artemisinin synergistically inhibit MDA-MB-231 cell proliferation through downregulation of testes-specific protease 50 (TSP50) expression.The molecule also targeted G2/M phase cell cycle along with targeting some key cell cycle related proteins including cyclin-B1, cyclin D1 and cyclin E. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | NA | |
| Cell line/ mice model | MCF-7, MDA-MB-231, P-388, A-549, HT-29, KB | |
| Additional information | Effectively blocks estrogen-stimulated cell cycle progression in MCF-7 cells Artemisinin and the pure antiestrogen fulvestrant exhibit cooperative reduction of ERalpha protein levels and enhanced G(1) cell cycle arrest Induces autophagy in MDA-MB-231 cisplatin-resistant human breast cancer cells by creating autophagosomes and autophagic vacuoles, and targets G2/M phase cell cycle along with key cell cycle related proteins including cyclin-B1, cyclin D1 and cyclin E 70 % 25-methoxyl-dammarane-3?, 12?, 20-triol and 30 % artemisinin, inhibit the TSP50-3'-UTR reporter activity and the expression of TSP50, inhibit MDA-MB-231 cell proliferation and induce cell cycle arrest. Could inhibit tumor growth in a xenograft model of breast cancer (IN VIVO) Artemisinin derivatives decrease expression and secretion of the angiogenic growth factor pleiotrophin by the cancer cells themselves, and inhibit angiogenesis in vivo and endothelial cell growth in vitro Shows strong anticancer effects in MDA-MB-231 cisplatin-resistant cancer cells by triggering apoptosis and autophagy and G2/M phase arrest Increases miR-34a expression correlating with down-regulation of the miR-34a target gene, CDK4 | |
| PubChem ID | 68827 | |
| Additional PMIDs | 18784357 8134418 32862573 25789847 25705665 32149317 25209896 31132755 27039397 27478545 27448920 28549888 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:304416-2 | |
| Safety | NA |